title: Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials.
abstract: In the treatment of acute bacterial skin and skin structure infections, pooled data from 2 clinical trials (N = 1333 patients) showed that programmatic and investigator-assessed early treatment success both had a high positive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients. The negative predictive value of programmatic early success was <20%. These exploratory findings require prospective real-world evaluation.
  
  
  BACKGROUND
  NCT01170221; NCT01421511.
authors.affiliation: Ninewells Hospital and Medical School, Dundee, United Kingdom.
authors.forename: Dilip
authors.initials: D
authors.lastname: Nathwani
authors.affiliation: Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
authors.forename: Ralph
authors.initials: R
authors.lastname: Corey
authors.affiliation: Biostatistics, InClin, San Mateo, California, and.
authors.forename: Anita F
authors.initials: AF
authors.lastname: Das
authors.affiliation: Merck Research Laboratories, Merck & Co, Inc., Kenilworth, New Jersey.
authors.forename: Taylor
authors.initials: T
authors.lastname: Sandison
authors.affiliation: Merck Research Laboratories, Merck & Co, Inc., Kenilworth, New Jersey.
authors.forename: Carisa
authors.initials: C
authors.lastname: De Anda
authors.affiliation: Merck Research Laboratories, Merck & Co, Inc., Kenilworth, New Jersey philippe.prokocimer@merck.com.
authors.forename: Philippe
authors.initials: P
authors.lastname: Prokocimer
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D000069349:Linezolid / Q000627:therapeutic use; D015233:Models, Statistical; D010755:Organophosphates / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; D000069349:Linezolid; C515040:tedizolid phosphate
keywords: ABSSSI; antibacterial therapy; oxazolidinones; tedizolid; treatment outcomes.